We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Day One Biopharmaceuticals, Inc. (DAWN - Free Report) shares rallied 26.7% in the last trading session to close at $11.33. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.9% gain over the past four weeks.
The stock rallied after the company reported robust preliminary sales numbers for the fourth quarter and full-year 2025 related to its lead marketed drug, Ojemda. The drug is approved for treating patients aged six months and older with relapsed or refractory BRAF-altered pediatric low-grade glioma.
Day One reported preliminary Ojemda net product revenues of approximately $52.8 million and $155.4 million for the fourth quarter and full year 2025, respectively. Full-year 2025 revenues increased 172% year over year. For full-year 2026, the company expects Ojemda net product revenue to be between $225 million and $250 million, representing 53% year-over-year growth at the midpoint.
This company is expected to post quarterly loss of $0.18 per share in its upcoming report, which represents a year-over-year change of +73.9%. Revenues are expected to be $43.25 million, up 48.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Day One Biopharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on DAWN going forward to see if this recent jump can turn into more strength down the road.
Day One Biopharmaceuticals is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, IDEAYA Biosciences, Inc. (IDYA - Free Report) , finished the last trading session 1.4% lower at $36.84. IDYA has returned 9.9% over the past month.
For IDEAYA Biosciences, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.03. This represents a change of +30.9% from what the company reported a year ago. IDEAYA Biosciences currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains?
Day One Biopharmaceuticals, Inc. (DAWN - Free Report) shares rallied 26.7% in the last trading session to close at $11.33. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.9% gain over the past four weeks.
The stock rallied after the company reported robust preliminary sales numbers for the fourth quarter and full-year 2025 related to its lead marketed drug, Ojemda. The drug is approved for treating patients aged six months and older with relapsed or refractory BRAF-altered pediatric low-grade glioma.
Day One reported preliminary Ojemda net product revenues of approximately $52.8 million and $155.4 million for the fourth quarter and full year 2025, respectively. Full-year 2025 revenues increased 172% year over year. For full-year 2026, the company expects Ojemda net product revenue to be between $225 million and $250 million, representing 53% year-over-year growth at the midpoint.
This company is expected to post quarterly loss of $0.18 per share in its upcoming report, which represents a year-over-year change of +73.9%. Revenues are expected to be $43.25 million, up 48.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Day One Biopharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on DAWN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Day One Biopharmaceuticals is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, IDEAYA Biosciences, Inc. (IDYA - Free Report) , finished the last trading session 1.4% lower at $36.84. IDYA has returned 9.9% over the past month.
For IDEAYA Biosciences, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.03. This represents a change of +30.9% from what the company reported a year ago. IDEAYA Biosciences currently has a Zacks Rank of #3 (Hold).